NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway
Trial Parameters
Brief Summary
Prostate cancer is the second most common cancer in men worldwide. The demand for magnetic resonance imaging (MRI) to diagnose and manage prostate cancer is continually growing. There is, however, a severe global shortage of radiologists who review and make decisions on prostate scans. This shortage causes compromises that are inefficient and negatively affect care provision, patient outcomes, and patient experiences. Two key examples of these compromises are that every patient receives a gadolinium contrast injection during a prostate MRI scan and patients often require multiple imaging appointments. If radiologists' knowledge of making prostate MRI decisions around these compromises could be harnessed and passed to radiographers (who are trained to acquire the MRIs but currently do not review them) with a computerised system to support clinical decision-making, this would have enormous potential to improve the diagnosing and managing prostate cancer.
Eligibility Criteria
Inclusion Criteria: * MRI radiographers in University Hospitals of North Midlands (UHNM) and or University Hospitals of Derby and Burton (UHDB) with over 5 years' experience in MRI of the prostate. * Radiographers from UHNM or UHDB who have completed an online and hands on study specific training materials before the testing phase. * Retrospective data of 800 patients each from UHNM and UHDB who have had mpMRI and went on to have a biopsy. Exclusion Criteria: * Non-MRI radiographers. * Radiographers who did not completed an online and hands on study specific training materials before the testing phase. * Non-mpMRI.